The discovery of kynurenic acid (KYNA) more than 150 years ago 1 , and the subsequent elucidation of its biosynthesis and chemical structure, initiated a series of discoveries that turned out to have important implications for the neurosciences. KYNA was the first of the 'kynurenines' , a group of metabolically related compounds derived from the essential amino acid tryptophan. Biochemical studies during the first part of the twentieth century delineated the enzymatic steps linking the individual members of the kynurenine pathway (FIG. 1) and found that this pathway accounts for >90% of peripheral tryptophan metabolism in mammals 2 . The importance of the pathway was long thought to stem mainly from the fact that it is a source of the coenzyme NAD + , which has a crucial role in many fundamental biological processes, including redox reactions required for mitochondrial function.
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Numerous studies since the 1970s have demonstrated that kynurenines can influence brain function. The past years have witnessed a surge in new information regarding the roles of kynurenine pathway metabolites not only in brain physiology but also as potential causative factors in several devastating brain diseases. In this Review, we first describe the properties of neuroactive kynurenines, their metabolism in the brain and the communication between the peripheral and the central kynurenine pathways. Using selected examples and focusing largely on in vivo evidence, we then explain how fluctuations in the level of kynurenine pathway metabolites can lead to the deterioration of physiological processes and the emergence of pathological states. Finally, we briefly review recent advances in drug discovery, which suggest exciting clinical applications of agents that are specifically designed to restore equilibrium in the cerebral kynurenine pathway.
Neuroactive kynurenines Kynurenic acid. KYNA is a competitive, broad-spectrum antagonist of glutamate receptors, inhibiting all three ionotropic excitatory amino acid receptors -NMDA receptors (NMDARs), kainate receptors and AMPA receptors (AMPARs) -to approximately the same degree at high micromolar concentrations 3 . KYNA has a greater affinity for the obligatory glycine co-agonist site of the NMDAR, so that this 'glycine B ' receptor constitutes a preferred molecular target 4 . Owing to the competitive nature of the action of KYNA at this site, selective glycine B receptor antagonists can substitute for KYNA 5 , and agonists can counter the actions of KYNA 6, 7 . During the past few years, additional targets of KYNA have been identified. Only one of them, the α7 nicotinic acetylcholine receptor (α7nAChR), has so far been verified as a bona fide KYNA receptor in the brain [8] [9] [10] [11] , whereas others, such as the former orphan G protein-coupled receptor GPR35 (REF. 12 ) and the aryl hydrocarbon receptor 13 , may be more relevant in the periphery 14 . Notably, the inhibitory action of KYNA at the α7nAChR, which can be readily observed on dendritic but not on somatic receptors 8, 15 , is non-competitive in nature, and the effector site of KYNA on the α7nAChR overlaps with the allosteric potentiating site that can be occupied by the cognition-enhancing drug galantamine 16 . Independent of its actions at receptors, KYNA also has antioxidant properties, which are related to its ability to scavenge hydroxyl, superoxide anion and other free radicals 17, 18 .
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. 3-HK and 3-HANA, in particular, readily autooxidize under physiological conditions, producing H 2 O 2 and highly reactive hydroxyl radicals in the process 24 . But these properties are balanced by the related antioxidant capacity of these compounds, and of xanthurenic acid, to scavenge peroxyl radicals 25 .
Quinolinic acid. The demonstration that an intracerebroventricular injection of quinolinic acid (QUIN) causes seizure activity in mice 26 provided the first evidence that kynurenine pathway metabolites can have central effects. The excitatory properties of QUIN are due to its direct, selective stimulation of NMDARs, as originally demonstrated using selective NMDAR antagonists 27 . Although its potency as an excitant is relatively low (half-maximal effective dose (ED 50 ): >100 μM), QUIN is remarkable for its preference for NMDARs in the forebrain. This regional selectivity is due to the fact that QUIN has a >tenfold lower affinity to the hindbrain-specific NR2C subunit of the NMDAR compared to the NR2B subunit, which predominates in the forebrain 28 . Differential subunit specificity notwithstanding, NMDAR activation seems to be obligatory for QUIN function as all neurobiological actions of QUIN described to date can be blocked by NMDAR antagonists.
QUIN also potently stimulates lipid peroxidation 29 , and this effect is strictly dependent on the presence of Fe 2+ ions 30 . The generation of reactive oxygen species by QUIN is secondary to the formation and auto-oxidation of Fe 2+ -QUIN complexes, and can be readily prevented by iron chelation 31 . Moreover, endogenous iron also directly controls the binding of QUIN to the NMDAR 32 .
Metabolism and regulation of brain kynurenines
Formed by a set of mostly glial enzymes (FIG. 1) , kynurenine pathway metabolites are normally present in the mammalian brain in concentrations in the nanomolar to low micromolar range [33] [34] [35] [36] [37] [38] . With one noteworthy exception -the high levels of KYNA in the human brain, which possibly signify exceptional neuroactive properties 36, 39 -species differences are relatively minor, although brain concentrations differ with age and between brain regions. The levels of the two tryptophan-degrading enzymes indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) in the . N-formylkynurenine is degraded by formamidase to yield the pivotal metabolite kynurenine. Compared to peripheral organs, the levels of these enzymes in the brain are normally low. Kynurenine undergoes irreversible transamination to form kynurenic acid (KYNA). Four kynurenine aminotransferases (KATs) have so far been shown to catalyse this reaction 200 . In the mammalian brain, KAT II is thought to be the main biosynthetic enzyme of KYNA as it does not recognize competing abundant amino acids as substrates 201 . No degradative enzyme of KYNA has yet been described in the mammalian brain. A second branch of the kynurenine pathway, competing with KYNA synthesis by KATs, is initiated by kynurenine 3-monooxygenase (KMO) and kynureninase, which catalyse the degradation of kynurenine to 3-hydroxykynurenine (3-HK) and anthranilic acid, respectively 188 . The in vivo disposition of kynurenine in the brain depends on the cellular localization, intracellular compartmentalization and kinetic characteristics of these two degradative enzymes, as well as KATs 44, 60 . Like kynurenine, 3-HK serves as a substrate of competing enzymes: kynureninase and KATs. Mammalian kynureninase preferentially recognizes 3-HK over kynurenine, catalysing the formation of 3-hydroxyanthranilic acid (3-HANA) 202 . Compared to peripheral organs, and for unknown reasons, anthranilic acid is a far better precursor of 3-HANA than 3-HK within the brain 33 . KAT II, and possibly other KATs, convert 3-HK to xanthurenic acid, which, like KYNA, appears to constitute a dead-end product of the kynurenine pathway. In addition to being oxidized to cinnabarinic acid, 3-HANA is the substrate of 3-hydroxyanthranilic acid 3,4-dioxygenase (3-HAO), which is present in relative abundance in the brain 203 , forming 2-amino-3-carboxymuconic-6-semialdehyde. The kynurenine pathway then branches into two arms. Under physiological conditions, 2-amino-3-carboxymuconic-6-semialdehyde spontaneously rearranges to form quinolinic acid (QUIN) with a half-life of approximately 20 minutes. QUIN synthesis may therefore be regulated both at the level of 3-HAO (for example, by changes in the concentration of Fe 2+ (REF. 204 )) and by changes in the intracellular milieu (such as pH and temperature) to influence the second, non-enzymatic step. Notably, the brain seems to contain very little 2-amino-3-carboxymuconic-6-semialdehyde decarboxylase, an enzyme that deflects the metabolic cascade towards the production of picolinic acid 205 . The cerebral activity of QUIN's degradative enzyme, quinolinate phosphoribosyltransferase, is very low 206 , making this enzyme one of the gatekeepers for the synthesis of NAD + (REFS 207, 208 brain are substantially lower than in peripheral tissues 40 , and approximately 60% of metabolism along the kynurenine pathway in the brain is initiated by the pivotal metabolite kynurenine 41 , which readily enters the brain from the circulation (see below) and is taken up by glial cells 42 . Intracerebral application of kynurenine in rats has revealed that approximately equal amounts of the primary degradation products 3-HK and KYNA are acutely produced from kynurenine under physiological conditions 43 . Notably, the synthesis of 3-HK and further downstream kynurenine pathway metabolites occurs in microglia, whereas KYNA is formed in astrocytes 44 . In other words, the two main arms of the kynurenine pathway are physically segregated in the brain (FIG. 2) .
In contrast to several other kynurenine pathway metabolites, and because of their polar nature and the apparent lack of efficacious transport processes, KYNA and QUIN cross the blood-brain barrier very poorly 45 and must be formed locally within the brain. Experimentally, both metabolites can be recovered from the extracellular milieu soon after their synthesis is stimulated by intracerebral infusions of their precursors kynurenine and 3-HANA, respectively 46, 47 . QUIN release appears to be controlled only by bioprecursor availability 48 , whereas the release of KYNA can be modulated by several factors. For example, KYNA formation and release decreases substantially in the presence of depolarizing stimuli such as high K + , glutamate receptor agonists or veratridine, or under hypoglycaemic conditions 49 . The decrease in KYNA levels during hypo glycaemia is linked to cellular energy metabolism and can be effectively reversed by adding lactate or pyruvate 50 . Like other 2-oxoacids, pyruvate also enhances the extracellular concentration of KYNA on its own by acting as a co-substrate in the transamination of kynurenine 51 (FIG. 2) . Interestingly, dopamine may have a specific regulatory role as well, as d-amphetamine reduces KYNA levels in the brain but not in the periphery 52 . Several of these effects are lost in the absence of neurons, indicating that KYNA production in, and release from, astrocytes is dependent on neuronal signals 49 . Finally, although specific organic anion transporters for KYNA might exist in the brain 53 , neither KYNA nor QUIN are efficiently removed from the extracellular compartment of the brain. Brain efflux therefore constitutes the major disposal mechanism for both metabolites 36, 54 .
Peripheral influences on the brain kynurenine pathway. Brain kynurenines are not autonomous but are linked to, and influenced by, the peripheral kynurenine pathway (FIG. 3) . In peripheral organs, levels of kynurenine pathway enzymes are far higher than in the brain and are regulated by steroids, growth factors and, most notoriously, several signalling molecules of the immune system [55] [56] [57] [58] . 60, 61 . Metabolism of the pathway is driven by blood-derived tryptophan (TRP), kynurenine (KYN) or 3-hydroxykynurenine (3-HK), or by locally formed metabolites. Of functional significance, the two branches of the pathway are physically segregated in the brain. Astrocytes, which harbour kynurenine aminotransferases (KATs) but do not contain kynurenine 3-monooxygenase (KMO) and therefore cannot produce 3-HK from KYN 44, [209] [210] , account for the biosynthesis of kynurenic acid (KYNA), which is regulated by intracellular metabolic events [49] [50] [51] . 3-HK and its major downstream metabolites are synthesized in microglia and other cells of monocytic origin 123, 211 . Once synthesized within glial cells, quinolinic acid (QUIN) and KYNA are promptly released into the extracellular milieu to affect their pre-and postsynaptic neuronal targets. 3-HANA, 3-hydroxyanthranilic acid; α7nAChR, α7 nicotinic acetylcholine receptor; NMDAR, NMDA receptor; TCA, tricarboxylic acid. It is uncertain to what extent these control mechanisms -including the stimulation of IDO by interferon-γ and other cytokines, which is the best-known mechanismoperate in the brain under physiological conditions 37, 59 . As tryptophan, kynurenine and 3-HK readily cross the blood-brain barrier 45 , it is clear, however, that fluctuations in the blood levels of these metabolites directly affect metabolism in the kynurenine pathway -including the synthesis of KYNA and QUIN -in the brain. Of note, because of the low levels of brain IDO and TDO under physiological conditions (see above), the effects of systemic tryptophan on the brain kynurenine pathway are, in part, driven by its peripheral conversion to kynurenine and 3-HK, and the subsequent entry of these metabolites into the brain (FIG. 3) .
Kynurenines in normal brain function
In early studies, the effects of KYNA and QUIN, the only neuroactive kynurenine pathway metabolites known at the time, were almost always tested at very high, non-physiological concentrations: that is, the two compounds essentially functioned as pharmacological probes to examine the downstream effects of glutamate receptor manipulations. These experiments revealed, not unexpectedly, a multitude of chemical and functional consequences, but they were not overly informative with regard to a role of endogenous kynurenines in the mammalian brain. Owing to a lack of appropriate experimental approaches, these studies also failed to identify possible effects of a selective reduction in brain KYNA or QUIN levels.
The development of increasingly specific and potent pharmacological agents targeting individual enzymes in the kynurenine pathway (see below and TABLE 1) has gradually begun to transform our understanding of the functional roles of kynurenines in the brain. Most of these 'kynurenergic' tools are still not ideal, and many of these compounds must be applied intracerebrally because they do not penetrate the blood-brain barrier after systemic administration. Nevertheless, the emerging tools allow investigations of endogenous kynurenine pathway metabolites in situ: that is, in an environment that maintains the natural anatomical arrangements between glial cells, which synthesize and release kynurenines, and adjacent neurons, which seem to play only a minor part in the production of kynurenine pathway metabolites 60, 61 . Studies in which KYNA is administered in concentrations in the endogenous range, studies using selective inhibitors of KYNA's main biosynthetic enzyme kynurenine aminotransferase II (KAT II) and studies using KAT II-knockout mice 62 have revealed a broad neuromodulatory role of KYNA on brain chemistry. Thus, within various regions of the rodent forebrain, even modest increases in KYNA cause prompt reductions in extracellular glutamate and dopamine levels [63] [64] , whereas KYNA synthesis inhibition raises the levels of these neurotransmitters 10, 65 , as well as acetylcholine levels 66 . Pharmacological experiments using selective α7nAChR agonists and antagonists (such as galantamine and methyllycaconitine, respectively) indicate 128,183 and also activate, or lead to the upregulation of, other kynurenine pathway enzymes, including tryptophan 2,3-dioxygenase (TDO) 212 and kynurenine 3-monooxygenase (KMO) 123, 138 . Jointly, they control the levels of circulating tryptophan, kynurenine and 3-hydroxykynurenine (3-HK), which all readily cross the bloodbrain barrier using the large neutral amino acid transporter 45 . Together with kynurenine pathway metabolism within glial cells, brain uptake of these kynurenines therefore determines kynurenine pathway flux in the brain. b | Inflammatory conditions stimulate the kynurenine pathway both in the periphery and in the brain. Activation of kynurenine pathway enzymes, especially IDO and KMO, in peripheral immune cells -such as dendritic cells 57, 58 and macrophages 123 -promotes the production of kynurenine and its downstream metabolites in the blood. Increased influx of the brain-permeable metabolites, in some cases aided by a leaky blood-brain barrier 181 , as well as infiltration of macrophages or microbial pathogens 117 , then leads to an excess of kynurenines in the brain parenchyma. Furthermore, infiltrating cytokines stimulate the kynurenine pathway in activated microglial cells and blood-borne cells within the brain 213 . Together, these peripheral and central events connect neuroinflammatory mechanisms with abnormal metabolism along the kynurenine pathway and brain pathology. KYNA, kynurenic acid; QUIN, quinolinic acid.
Pre-pulse inhibition (PPI) . A reduction in the magnitude of the startle reflex that occurs when an organism is presented with a non-startling stimulus (a pre-pulse) before being presented with the startling stimulus. Deficits in PPI have been observed in patients with schizophrenia.
that α7nAChRs, rather than NMDARs, are the primary target of endogenous KYNA in the normal brain in vivo and mediate the bi-directional effects of KYNA on neuro transmitter levels 10, 63, 64 . This suggests, conversely, that α7nAChRs and their many physiological functions 67 are controlled by endogenous KYNA.
Fluctuations in brain KYNA levels have distinct behavioural consequences, especially related to cognition. Administered to normal rats and following conversion to nanomolar or low micromolar concentrations of KYNA in the brain, systemic administration of kynurenine causes impairments in visuospatial working memory, contextual learning, sensory gating and pre-pulse inhibition of the acoustic startle reflex -all behaviours linked to cholinergic, glutamatergic and dopaminergic neurotransmission [68] [69] [70] [71] . Notably, the effect of KYNA on dopaminergic neurotransmission has also been convincingly demonstrated electrophysiologically. Thus, systemic administration of kynurenine or a relatively moderate increase in brain KYNA levels by pharmacological means reliably affects the firing of dopaminergic neurons in the midbrain, influencing downstream projection areas such as the striatum, the nucleus accumbens and the prefrontal cortex 72, 73 . Conversely, specific reductions in brain KYNA levels caused by genetic elimination of KAT II or acute administration of a KAT II inhibitor improve contextual memory and spatial discrimination 74 and enhance spatial memory 75 (see below). Additional mutant mice and enzyme inhibitors (TABLE 1) have recently become available for studying the complex interplay of peripheral and central kynurenines. These experimental tools are beginning to be used to systematically examine the physiological roles of kynurenine pathway metabolites in the brain and elsewhere 60, [76] [77] [78] .
Kynurenines in neurological diseases
Kynurenines did not attract much attention from neurobiologists until the pathological effects of QUIN in the brain were recognized three decades ago. In addition to its usefulness as a readily available, easy-to-use and inexpensive excitotoxin, QUIN became recognized for its ability to model neuropathological, neurochemical and clinical features of human diseases such as Huntington's disease and temporal lobe epilepsy 79 , raising the spectre that an abundance of endogenous QUIN might have a causative role in the pathophysiology of these and other neurological diseases. The discovery of the neuroprotective and anticonvulsant effects of KYNA 80 then led to the idea that a reduction in endogenous KYNA or, more generally, any process resulting in an abnormal increase in the QUIN/KYNA ratio in the brain might trigger neuronal lesions in various conditions linked to excitotoxic phenomena [81] [82] [83] . However, scepticism concerning a possible pathogenic role of endogenous kynurenine pathway metabolites abounded, especially because endogenous concentrations of QUIN and KYNA in the brain are orders of magnitude lower than those needed to model neurological diseases acutely in rodents or primates in vivo.
Huntington's disease. Evidence for a pathophysiologically significant role of abnormal metabolism in the kynurenine pathway is most compelling in the case of Huntington's disease, the first and prototypical disease linked to an excitotoxic mechanism 84 . Studies in postmortem brains revealed that QUIN levels are substantially increased in the initial stages of the disease, and especially in those brain regions (the neostriatum and cortex) that suffer the most damage 85 . This increase, which coincides with early activation of microglia 86 , results in QUIN concentrations that are clearly capable of producing excitotoxic neuronal damage 87, 88 . Notably, the increase in brain QUIN levels in Huntington's disease is accompanied by a quantitatively similar increase in cerebral 3-HK levels 85, 89 . The concentrations of 3-HK reached in the disease are neurotoxic to striatal neurons but, interestingly, not to cerebellar neurons 90 . Of possible pathogenic significance, the neurotoxic properties of these two microglia-derived kynurenine pathway metabolites are synergistic 91, 92 . Reductions in brain KYNA levels in Huntington's disease 93 could be physiologically relevant as well, as a deficiency in KYNA enhances vulnerability to QUIN neurotoxicity 94 . Similar changes in the cerebral kynurenine pathway -most reliably the increase in 3-HK levels -have been found in mouse models of Huntington's disease 95, 96 . The most persuasive arguments for a causative link between abnormal kynurenine pathway function and Huntington's disease pathology come from studies in lower model organisms. Thus, a genome-wide loss-of-function screen in yeast showed that the deletion of kynurenine 3-monooxygenase (KMO), which converts kynurenine into 3-HK (FIG. 1) , potently suppresses the toxicity of a mutant huntingtin fragment, and that elimination of KAT exacerbates toxicity 97 . Notably, deletion of the gene encoding 3-hydroxyanthranilic acid dioxygenase (3-HAO) (which metabolizes 3-HANA to QUIN) also suppresses mutant huntingtin toxicity. Surprisingly, the majority of functionally unrelated genetic suppressors of mutant huntingtin toxicity in yeast decrease the levels of 3-HK and QUIN, suggesting that the kynurenine pathway has a crucial downstream role in the toxic effects of mutant huntingtin 98 . As yeast do not have glutamate receptors, abnormal mitochondrial function and reactive oxygen species, rather than excitotoxicity, probably link kynurenine pathway manipulations to cell death in this model of Huntington's disease. These factors may also contribute to some aspects of neurodegeneration in the human disease 97 . In a transgenic Drosophila melanogaster model of Huntington's disease, genetic or pharmacological KMO inhibition increased levels of KYNA relative to 3-HK (flies do not produce QUIN) and ameliorated neurodegeneration. Underscoring the roles of 3-HK and KYNA in neuropathology, the neuroprotective effect of KMO inhibition was reduced by feeding the flies 3-HK, whereas feeding KYNA attenuated neurodegeneration. These interventions had no obvious effects in wild-type control flies, indicating that vulnerable organisms are excessively sensitive to manipulations of the kynurenine pathway 99 .
Pro-inflammatory cytokines
Other neurological diseases. Cerebral kynurenine pathway changes also occur in other neurodegenerative diseases, although this aspect has not been studied comprehensively. In the basal ganglia of patients with Parkinson's disease, the concentration of 3-HK is increased, whereas kynurenine and KYNA levels are slightly reduced 100 . In Alzheimer's disease, QUIN immuno reactivity is strongest in glial cells in close proximity to amyloid plaques and also labels neurofibrillary tangles, suggesting that QUIN-induced excitotoxicity or oxidative stress might participate in the pathogenic process 101 . Immunocytochemical studies of IDO and 3-HK provide further evidence that the kynurenine pathway is upregulated in the disease 102 . Also indicative of a role of the kynurenine pathway in Alzheimer's disease, QUIN induces tau phosphorylation in cultured primary human neurons 103 .
As predicted from studies in rodent models 26, [104] [105] [106] , human seizure disorders are also associated with abnormal cerebral kynurenine pathway activity. Of special interest, this impairment can be documented non-invasively by positron emission tomography using 11 C-α-methyl-l-tryptophan as a tracer. This in vivo imaging methodology, which has so far been used mainly in glioma and epilepsy research, allows the simultaneous assessment of serotonin and kynurenine synthesis in the human brain with high specificity and good sensitivity. The technology has revealed enhanced tryptophan retention and subsequent activation of kynurenine pathway metabolism in gliotic tissue, and can be used to identify epileptogenic lesions interictally and to guide tissue resection during surgery in patients with epilepsy 107 . Once kynurenine pathway metabolites downstream from kynurenine can be reliably identified through further methodological improvements, such imaging techniques -applied longitudinally and in combination with assessments of kynurenine pathway metabolites in blood and cerebrospinal fluid (CSF) -could revolutionize our understanding of kynurenine pathway neurobiology in health and disease.
Studies in animal models have shown that connections between abnormal kynurenine pathway metabolism and neuropathology also exist in animals experiencing acute metabolic or physical insults, such as hypoglycaemia 108 , cerebral ischaemia 109 , perinatal hypoxia 110 or traumatic spinal cord injury 111 , even though these non-specific events clearly induce and probably involve a multitude of additional pathogenic mechanisms.
Because of the complex interactions between peripheral and central kynurenine pathways, studies describing kynurenine pathway abnormalities in blood, cultured cells and CSF in various human neurological disorders (see for reviews) are not unequivocally instructive about the contribution of these abnormalities to the disease. Nevertheless, such studies, including the numerous demonstrations of peripheral IDO activation in neurological disorders, are often useful as predictors and indicators of abnormal kynurenine pathway function within the brain (see below). They can also help to assess the involvement of kynurenine pathway abnormalities in models of neurological diseases, especially those induced by known pathogens, for example malaria or trypanosome parasites [115] [116] [117] .
The role of inflammatory mechanisms.
Together with other, disease-specific aetiological factors, chronic neuro inflammation plays an increasingly appreciated part in the pathogenesis of a large number of neurological diseases 118, 119 . Underlying events include brain infiltration of circulating immune cells, activation of resident microglia and other non-neuronal cells, and brain influx of blood-derived, pro-inflammatory cytokines and other immune activators. Brain invasion of macrophages is especially noteworthy in this regard, as these cells have a more than 20-fold higher capacity to produce QUIN than microglial cells 120 . Alone or jointly, these mechanisms are responsible for the enhanced synthesis of kynurenine from tryptophan within the brain 37, 59 and the subsequent activation of the cerebral kynurenine pathway. In fact, both systemic and central immune stimulation, including cytokine-induced IDO activation, may contribute to cerebral kynurenine pathway activation in neurological disorders (FIG. 3) . Not un expectedly, therefore, the brain kynurenine pathway is often stimulated in diseases of viral origin. Common to all these diseases, increases in 3-HK and QUIN levels in the brain outweigh the increase in KYNA levels by substantial margins -most dramatically in the case of HIV-1-infected individuals 121, 122 . This robust increase in neurotoxic meta bolites suggests that blood-derived or
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locally produced kynurenine is preferentially degraded within activated microglial cells and macrophages 123 but is less available for sequestration to KYNA in astrocytes (FIG. 3) .
Kynurenines in psychiatric disorders
Major depressive disorders. Speculation about a role of kynurenines in major depressive disorders dates back several decades, to the time when the connection between depression, tryptophan and serotonin was first recognized 124 . However, the exceptional success of serotonin reuptake inhibitors as antidepressants, paired with the lack of consistent indications of kynurenine pathway changes in depression, essentially stifled efforts to explore a possible involvement of kynurenine pathway metabolites in pathophysiology. However, studies performed during the past 10 years have led to a paradigm shift in this regard, and kynurenine pathway dysfunction is now increasingly recognized as a major player in the development and symptomatology of depressive disorders. Similar in principle to the above-mentioned neuroimmune hypothesis of neurological disorders, the pathophysiological concept is based on the realization that the kynurenine/tryptophan ratio in blood is enhanced in patients with depression and correlates with anxiety and cognitive deficits but not with neurovegetative or somatic symptoms 125, 126 . Several lines of evidence indicate that immune system activation of IDO has a central role here. First, a number of pro-inflammatory cytokines that are known to stimulate IDO, such as interferon-α, induce depressive symptoms in patients suffering from cancer or chronic hepatitis C 126, 127 . Second, following bacterial infection in mice, chronic upregulation of IDO by interferon-γ or tumour necrosis factor-α induces long-lasting depressive-like behaviours, and these effects are blocked in IDO-deficient mice or when the increase in IDO activity is attenuated by pharmacological means 128, 129 . Finally, vulnerability to cytokine-induced depression is associated with a polymorphism in IDO1 (REF. 130 ), providing a possible explanation for clinical heterogeneity in the occurrence of depressive symptoms following stimulation of the immune system. Interestingly, bacterial infection also stimulates IDO activity in the placenta 131 , suggesting that it may contribute to post-partum depression 132 . How systemic IDO activation -that is, an excess of circulating kynurenine -might lead to depressive behaviours is unclear. Immunohistochemical studies show some microglial activation (and QUIN immunoreactivity) as well as a reduction in astrocyte numbers in animal models of depression and in post-mortem brains of patients with major depression [133] [134] [135] [136] . As in neurological diseases (although to a lesser extent), enhanced kynurenine influx from the periphery may increase the ratio between the neurotoxic metabolites -that is, 3-HK and QUIN -and the neuroprotective KYNA. This could augment neuronal vulnerability and adversely affect, for example, the viability of newly generated hippocampal neurons 137, 138 , which are arguably necessary to avert or attenuate depression. QUINinduced overactivation of NMDARs in depression might also explain why NMDAR antagonists possess antidepressant properties 139 . However, QUIN and KYNA levels are equally enhanced in the CSF after immune stimulation with interferon-α in humans 127 , suggesting a more complicated scenario. Moreover, any changes in the cerebral kynurenine pathway in depression may be brain region-specific, as 3-HK levels are reduced in the cortex but enhanced in the striatum and amygdala in an established mouse model of the disease 140 . Definitive resolution of the respective roles of the two kynurenine pathway branches in depression, including their possible effects on the neurocircuitry that underlies the cognitive deficits associated with the disease 141 , must therefore await improved imaging of brain kynurenine pathway metabolism (see above) and targeted pharmacological interventions in humans and appropriate animal models.
Schizophrenia. Assessment of kynurenine pathway involvement in schizophrenia initially followed a similar trajectory to that for major depression, with early studies failing to establish pathophysiologically significant links 142 . The realization that the psychotomimetic drug ketamine, which produces schizophrenia-like symptoms in normal individuals and exacerbates psychotic features in patients with schizophrenia 143, 144 , functions as an NMDAR antagonist 145 led to the idea that the presence of excessive KYNA or an increased ratio between KYNA and 3-HK (and its downstream metabolites) might, by reducing NMDAR activity, have a role in schizophrenia pathology 146 . Brain levels of KYNA are indeed increased in post-mortem brains of patients with schizophrenia, and this increase, which is also seen in the CSF, is unrelated to chronic medication with antipsychotic drugs [147] [148] [149] [150] . Brain levels of 3-HK, however, are unchanged 148 . Measurements of the expression and activity of kynurenine pathway enzymes in brain areas that are known to be involved in schizophrenia pathology (that is, in the frontal and anterior cingulate cortices) suggest a scenario in which a reduction in KMO 150, 151 , combined with an increase in TDO 152, 153 , increases kynurenine levels and thereby shifts kynurenine pathway metabolism towards enhanced KYNA formation (FIG. 1) . Kynurenine levels are, in fact, increased in the prefrontal cortex and CSF in patients with schizophrenia 148, 154 , possibly as a consequence of peripheral neuroinflammation, which exists in schizophrenia as well 155, 156 (FIG. 3) . As explained earlier, a preferential increase in KYNA levels, leading to tissue concentrations in the high nanomolar range, would then result in increased inhibition of α7nAChRs, subsequently causing an imbalance in glutamate, dopamine and acetylcholine systems, all of which have been linked to schizophrenia pathology [95] [96] [97] [98] [99] 157 . Studies in animals and humans indicate that increased KYNA levels may be especially relevant for the cognitive deficits seen in schizophrenia. Thus, in rats, an acute rise in KYNA levels in the prefrontal cortex causes the characteristic impairment in cognitive flexibility seen in schizophrenia 158, 159 . Moreover, experimentally induced increases in KYNA synthesis in the developing brain, perhaps mimicking prodromal events in schizophrenia, produce long-lasting deficits in Nature Reviews | Neuroscience spatial and contextual learning and memory, as well as impaired cognitive flexibility, in the adult animal [160] [161] [162] [163] . Finally, in patients with schizophrenia, a single-nucleotide polymorphism in the KMO gene is associated with impairments in smooth pursuit eye movement and visuospatial working memory 151, 164 . The study of kynurenine pathway metabolism in schizophrenia, and possibly also in other psychiatric diseases (such as bipolar disorder, drug abuse and autism spectrum disorders [165] [166] [167] ), may therefore be particularly rewarding using an approach focused on distinct sub-domains of psychopathology (endophenotypes).
Targeting the kynurenine pathway An increasingly diverse armamentarium of pharmacological agents has been developed for the study of the kynurenine pathway in health and disease (TABLE 1) . Alone or in combination with exogenously supplied kynurenines, specific enzyme inhibitors can now be used to examine physiological events in the brain and to normalize cerebral kynurenine pathway function when needed. Two classes of inhibitors, targeting KAT II and KMO, respectively, have so far contributed most to our understanding of kynurenine pathway neurobiology.
KAT II inhibitors. The first-generation KAT II-specific inhibitor (S)-4-(ethylsulphonyl)benzoylalanine (ESBA), was introduced in 2006 (REF. 168
) and turned out to be an excellent tool for examining the disposition and function of endogenous KYNA in the rat brain. Irrespective of brain region and dosage, intracerebral application of ESBA or other KAT II inhibitors causes no more than a 30-40% reduction in extracellular KYNA, indicating that KAT II controls only a fraction of KYNA synthesis in the extracellular milieu in vivo. This relatively small decrease is sufficient, however, to increase the extracellular concentrations of glutamate, dopamine and acetylcholine: that is, the same neurotransmitters that are reduced when KYNA levels are even moderately increased (see above). This suggests that the KAT II-dependent pool of KYNA, which can be readily mobilized, provides tonic inhibition of its central receptor target (or targets). Notably, preliminary data show that the pro-cognitive effects of genetic elimination of KAT II 74 or acute application of ESBA 75 (FIG. 4) mentioned above can be duplicated by administration of secondgeneration, brain-penetrable KAT II inhibitors 169, 170 , and that this intervention also attenuates ketamine-induced working memory deficits in monkeys 171, 172 . These results bode well for the use of KAT II inhibitors in humans, especially in diseases such as schizophrenia, in which cognitive deficits might be related to high levels of KYNA in the brain (FIG. 5) .
KMO inhibitors. First-generation KMO inhibitors demonstrated anticonvulsant and neuroprotective efficacy in various model systems in vivo 94, 99, [173] [174] [175] . Ro 61-8048, the most widely used KMO inhibitor, was introduced in 1997 (REF. 176 ). This compound has pronounced neuroprotective and antidyskinetic effects when used 
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systemically in animal models of focal or global ischaemia 177 and l-dopa-induced dyskinesia 178 , respectively. Ro 61-8048 also has substantial anti-inflammatory effects in an animal model of sleeping sickness 117 and delays death in a mouse model of cerebral malaria 179 . Like all KMO inhibitors tested so far, Ro 61-8048 raises brain KYNA levels following systemic application, and this increase is probably responsible for the remarkable central effects of the compound. In normal animals, the increase in brain KYNA levels is not accompanied by a reduction in the levels of brain 3-HK and QUIN, suggesting that the enzyme inhibitor does not cross the blood-brain barrier. This was verified in a recent study demonstrating neuroprotection with JM6, a pro-drug of Ro 61-8048, in mouse models of Huntington's disease and Alzheimer's disease (FIG. 4) . Thus, the beneficial effects of JM6 treatment were achieved exclusively through peripheral KMO inhibition, leading to moderate, persistent increases in brain KYNA levels 180 . Interestingly, application of a KMO inhibitor in conditions of strong immune stimulation, perhaps involving KMO blockade in activated endothelial cells and pericytes of the blood-brain barrier, causes a reduction in brain 3-HK and QUIN levels within the brain parenchyma 181, 182 . This may provide additional benefit to patients with neurodegenerative diseases (FIG. 5) .
Other kynurenine pathway inhibitors. Inhibitors of IDO and TDO, which are prominent as potential cancer therapies 183, 184 , have so far not been used to study the cerebral kynurenine pathway directly, although these enzyme inhibitors might offer innovative, novel treatment options for neurological and psychiatric diseases that are caused or exacerbated by immune system dysfunction. Notably, however, inhibition of IDO (and possibly also of TDO 185 ) may have harmful effects as well, considering that the enzyme plays a crucial part in the suppression of T cell activity under inflammatory conditions 186, 187 . This suppressive effect can be harnessed to limit pathology in chronic infectious and autoimmune diseases 186, 187 but can be harmful in other conditions. Of other agents specifically targeting individual kynurenine pathway enzymes, kynureninase inhibitors 188, 189 and the 3-HAO inhibitor 4-Cl-3-hydroxyanthranilic acid 190 have been sparingly but successfully used in neurobiological research. Most interestingly, 4-Cl-3-hydroxyanthranilic acid, an effective blocker of microglial QUIN neosynthesis in vivo 191 , preserves white matter and effects functional recovery in a model of spinal cord injury without enhancing KYNA levels 192 .
Challenges for future research It is clear that the kynurenine pathway, a highly conserved metabolic machinery, has evolved to serve important regulatory functions in the mammalian brain. As we explore the largely unknown role (or roles) of kynurenines in cell biology, we are likely to uncover the functional significance of distinct intracellular processes they might influence. Specific questions abound. For example, does the strict association of KMO with the outer mitochondrial membrane 193 signify a specific 85, 89, 96 . Conversely, lowering of the KYNA/3-HK ratio in the brain will improve cognitive capabilities, providing special benefits in diseases, such as schizophrenia, that show increased brain levels of KYNA 148 . In the normal brain, fluctuations in the metabolite ratio, limited to the physiological range, will have moderate effects on neuronal viability and cognition. Pharmacological interventions with specific 'kynurenergic' agents, such as KAT II or KMO inhibitors, should therefore be tailored to achieve the intended benefits and minimize potentially harmful consequences.
Apoptotic cell death
Innate, programmed cell death that is energy-dependent and leads to nuclear and cytoplasmic compaction with characteristic blebbing of the nucleus. It occurs during development but also in disease states.
Homeostasis
The process whereby an open or closed system regulates its internal environment to maintain its states within bounds.
mitochondrial function of 3-HK or downstream metabolites? More generally, is there a physiological role for the pro-and antioxidative effects of KYNA, 3-HK and 3-HANA 17, 18, [23] [24] [25] , or for the ability of QUIN 31 or picolinic acid 194 to chelate bioactive metal ions? Are any of these intracellular functions brain-specific, and do they differ between various glial cells or between resting and activated glia? If so, what are the functional consequences of this diversity? Furthermore, how is brain function influenced by the role of kynurenine in regulating microvascular tone (that is, cerebral blood flow) 116 
?
Another promising line of investigation, which has been only sparingly pursued so far 131, 195, 196 , will explore the possibility that the role of brain kynurenines changes over the course of the lifespan. Do kynurenines derived from the mother shape metabolism along the kynurenine pathway and the function of pathway metabolites in the fetal brain? Do kynurenines, perhaps through their involvement in mitochondrial processes and oxidative stress, contribute to apoptotic cell death in the aged brain? Or, more generally, are the neuromodulatory effects of kynurenines age-specific, perhaps involving qualitatively distinct intra-and intercellular mechanisms during brain development and during ageing?
Further elucidation of the mechanisms that control and maintain equilibrium between peripheral and central kynurenine pathways in mammals will probably remain a major research objective for several reasons. First, normal homeostasis between the two compartments is delicate and complex, and is influenced by a considerable number of environmental and physiological factors.
These mechanisms are still poorly understood. Second, as briefly reviewed here, changes in the levels of circulating kynurenines under inflammatory conditions can either increase (in neurological disorders) or reduce (in schizophrenia) the ratio between neurotoxic and neuro protective kynurenine pathway metabolites in the brain. Resolution of this puzzling quandary, which has pathophysiologically relevant implications, will require a thorough assessment of kynurenine pathway function in multiple brain cell types and various disease models. These studies will clarify, in essence, how physiology can be usurped to produce distinct brain pathologies. Finally, new information is needed to confidently predict the desired physiological effects or clinical improvements caused by selective kynurenine pathway enzyme inhibitors (see above). To optimize efficacy and minimize the risk of adverse side effects, especially when used in conjunction with other drugs, it will be especially important to develop new, potent pharmacological agents that can be used to discriminate between the consequences of peripheral and central enzyme inhibition and to compare acute and chronic effects of the novel compounds. As shown in FIG. 5 , which illustrates the effects of manipulating the KYNA/3-HK ratio in the brain under physiological and pathological conditions, interventions with specific 'kynurenergic' drugs must then be carefully tailored to achieve the intended benefit and avoid harmful outcomes. Successful improvement of brain function or effective treatment of brain disorders by selective targeting of individual kynurenines in the human brain would constitute the ultimate reward of these efforts.
